Becton, Dickinson and Company (NYSE:BDX) Stock Unloaded Rep. Kevin Hern

Posted by Hanz Christensen on Apr 7th, 2026

Representative Kevin Hern (Republican-Oklahoma) recently sold shares of Becton, Dickinson and Company (NYSE:BDX). In a filing disclosed on April 03rd, the Representative disclosed that they had sold between $15,001 and $50,000 in Becton, Dickinson and Company stock on March 17th. The trade occurred in the Representative’s “HERN FAMILY REVOCABLE TRUST” account.

Representative Kevin Hern also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of Exact Sciences (NASDAQ:EXAS) on 3/24/2026.
Sold $50,001 – $100,000 in shares of Prologis (NYSE:PLD) on 3/20/2026.
Sold $15,001 – $50,000 in shares of T. Rowe Price Group (NASDAQ:TROW) on 3/20/2026.
Sold $15,001 – $50,000 in shares of Medtronic (NYSE:MDT) on 3/20/2026.
Sold $500,001 – $1,000,000 in shares of Texas Instruments (NASDAQ:TXN) on 3/18/2026.
Sold $500,001 – $1,000,000 in shares of Smartstop Self Storage REIT (NYSE:SMA) on 3/18/2026.
Sold $50,001 – $100,000 in shares of BlackRock MuniAssets Fund (NYSE:MUA) on 3/17/2026.
Sold $15,001 – $50,000 in shares of Cognizant Technology Solutions (NASDAQ:CTSH) on 3/17/2026.
Sold $15,001 – $50,000 in shares of Invesco (NYSE:IVZ) on 3/17/2026.
Sold $15,001 – $50,000 in shares of Comcast (NASDAQ:CMCSA) on 3/17/2026.

Becton, Dickinson and Company Trading Up 0.4%

Shares of NYSE BDX opened at $155.13 on Tuesday. The company has a quick ratio of 0.58, a current ratio of 1.05 and a debt-to-equity ratio of 0.67. The business has a fifty day simple moving average of $174.72 and a two-hundred day simple moving average of $186.24. The firm has a market cap of $44.17 billion, a PE ratio of 25.31, a price-to-earnings-growth ratio of 11.20 and a beta of 0.29. Becton, Dickinson and Company has a twelve month low of $127.59 and a twelve month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share for the quarter, beating analysts’ consensus estimates of $2.81 by $0.10. The business had revenue of $4.49 billion during the quarter, compared to analyst estimates of $5.15 billion. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.Becton, Dickinson and Company’s revenue was up 1.6% on a year-over-year basis. During the same period in the previous year, the company posted $3.43 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. Analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th were given a dividend of $1.05 per share. The ex-dividend date of this dividend was Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a yield of 2.7%. Becton, Dickinson and Company’s payout ratio is 68.52%.

Becton, Dickinson and Company announced that its Board of Directors has authorized a share buyback plan on Tuesday, January 27th that permits the company to buyback $10.00 million in shares. This buyback authorization permits the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares buyback plans are often an indication that the company’s leadership believes its stock is undervalued.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in BDX. Brighton Jones LLC raised its position in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock worth $401,000 after acquiring an additional 877 shares in the last quarter. Empowered Funds LLC raised its position in shares of Becton, Dickinson and Company by 20.4% in the 1st quarter. Empowered Funds LLC now owns 7,977 shares of the medical instruments supplier’s stock worth $1,827,000 after acquiring an additional 1,354 shares in the last quarter. United Bank raised its position in shares of Becton, Dickinson and Company by 23.9% in the 2nd quarter. United Bank now owns 5,149 shares of the medical instruments supplier’s stock worth $887,000 after acquiring an additional 993 shares in the last quarter. Northwestern Mutual Wealth Management Co. raised its position in shares of Becton, Dickinson and Company by 9.0% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 15,402 shares of the medical instruments supplier’s stock worth $2,653,000 after acquiring an additional 1,266 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership purchased a new position in Becton, Dickinson and Company during the 2nd quarter worth $33,993,000. 86.97% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BDX. Bank of America lifted their target price on Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research report on Monday, January 5th. Barclays began coverage on Becton, Dickinson and Company in a research report on Tuesday, February 10th. They set an “overweight” rating and a $202.00 target price for the company. Piper Sandler reaffirmed a “neutral” rating and set a $170.00 target price (down from $205.00) on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. TD Cowen lifted their target price on Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a “hold” rating in a research report on Wednesday, February 11th. Finally, JPMorgan Chase & Co. decreased their target price on Becton, Dickinson and Company from $190.00 to $175.00 and set a “neutral” rating for the company in a research report on Tuesday, February 10th. Six equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $191.62.

Get Our Latest Analysis on BDX

Insider Activity

In related news, EVP Michael David Garrison sold 1,610 shares of the company’s stock in a transaction dated Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the transaction, the executive vice president directly owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This represents a 11.75% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Bertram L. Scott sold 953 shares of the company’s stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the transaction, the director directly owned 36,763 shares in the company, valued at $6,713,291.43. This represents a 2.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 2,713 shares of company stock worth $536,881 over the last ninety days. 0.40% of the stock is currently owned by corporate insiders.

About Representative Hern

Kevin Hern (Republican Party) is a member of the U.S. House, representing Oklahoma’s 1st Congressional District. He assumed office on November 13, 2018. His current term ends on January 3, 2027.

Hern (Republican Party) is running for re-election to the U.S. House to represent Oklahoma’s 1st Congressional District. He declared candidacy for the 2026 election.

Kevin Hern went into business as a McDonald’s franchisee in 1999. He acquired 10 McDonald’s franchises by 2012. He served on the McDonald’s National Leadership Team for 13 years, including the tax policy team, the insurance corporation, and as chairman of the economics team. From 2011 to 2015, he was chairman of the finance committee of the Oklahoma Turnpike Authority.

About Becton, Dickinson and Company

(Get Free Report)

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.